EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

Cyrus Daruwalla iD, Courtney Kremler, Francesco Patti, Serkan Ozakbas, Cavit Boz, Jeannette Lechner-Scott, Andrea Surcinelli, Matteo Foschi, Samia J Khoury, Helmut Butzkueven, Anneke van der Walt, Zuzana Rous und 48 weitere

Brain · 24.07.2026

DOI: 10.1093/brain/awag252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 24.07.2026. Verfasst von Cyrus Daruwalla und 59 weiteren Autor:innen. Beteiligte Einrichtung: Cambridge Clinical Multiple Sclerosis Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research, NIHR Cambridge Biomedical Research Centre, Association of British Neurologists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease-modifying therapy (DMT). Guidelines only routinely recommend DMT escalation after multiple silent lesions, and adherence is variable. We explored outcomes and the effect of treatment escalation following single and multiple on-treatment silent lesions. This cohort study and emulated target trial used MSBase registry data from 99 clinics in 26 countries between 2007 and 2025. Clinically stable participants receiving any DMT for RRMS with silent lesions versus without silent lesions were compared. Among participants with silent lesions while taking platform or moderate-efficacy DMTs, outcomes following treatment escalation within 6 months versus no treatment escalation (unless a post-MRI clinical event occurred) were compared. The primary outcome was an MS relapse, and the secondary outcome was 6-month confirmed disability worsening. A total of 10 232 participants met inclusion criteria [71.7% female, mean age 41 (standard deviation 11)]. The 2-year cumulative incidence of relapse was 27.8% [95% confidence interval (CI): 25.7%–29.9%] in participants with silent lesions versus 14.3% (95% CI: 13.5%–15.2%) without [adjusted hazard ratio (aHR) 1.76 (95% CI: 1.57–1.97)]. The 2-year cumulative incidence of disability worsening was 13.8% (95% CI: 12.2%–15.5%) in participants with silent lesions versus 11.4% (95% CI: 10.7%–12.2%) without [aHR 1.38 (95% CI: 1.18–1.62)]. Rates of relapse and disability worsening were higher following single and multiple silent lesions versus no silent lesions. The emulated trial included 2264 participants with ≥1 silent lesion on platform or moderate efficacy DMTs, 286 of whom escalated DMT within 6 months following silent lesions. The 4-year cumulative incidence of relapse was lower following treatment escalation [16.8% (95% CI: 12.4%–23.4%)] versus continuation [38.9% (95% CI: 35.8%–42.1%)], aHR 0.34 (95% CI: 0.23–0.47), with similar aHRs following single and multiple silent lesions. The 4-year cumulative incidence of disability worsening was similar following treatment escalation [16.0% (95% CI: 10.8%–22.2%)] versus continuation [17.7% (95% CI: 15.3%–20.1%)], aHR 0.89 (95% CI: 0.56–1.33). People with RRMS with single or multiple on-treatment silent MRI lesions have higher subsequent risks of relapse and disability worsening than people without silent lesions. DMT escalation mitigates the relapse risk, though disability worsening continues at a similar rate over 4 years. Contrary to guidelines, DMT escalation should be considered after single or multiple silent lesions.

Schlagwörter

Stichwörter der Autor:innen

disease activityisolated MRI activityisolated radiological activitysilent MRI lesiontarget trial emulationtreatment strategy

Autor:innen und Institutionen

  • Cambridge Clinical Multiple Sclerosis Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0QQ, UK.
  • Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
  • Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, 95123 Catania, Italy.
  • Multiple Sclerosis Unit, AOU Policlinico G Rodolico-San Marco, University of Catania; 95123 Catania, Italy.
  • Izmir University of Economics, Medical Point Hospital, 35575 Izmir, Turkey.
  • Multiple Sclerosis Research Association, 35320 Izmir, Turkey.

ORCID-Profile: Cyrus Daruwalla, Pamela McCombe, Bruce Taylor, Yi Chao Foong, Simón Cárdenas-Robledo, Emanuele D'Amico, Michael Barnett, Jens Kuhle

Förderung

  • National Institute for Health Research
  • NIHR Cambridge Biomedical Research Centre
  • Association of British Neurologists
  • Patrick Berthoud Charitable Trust
  • Addenbrooke’s Charitable Trust, Cambridge University Hospitals
  • MS Society
  • National Health and Medical Research Council

Zitieren

APA

Daruwalla, C., Kremler, C., Patti, F., Ozakbas, S., Boz, C., Lechner-Scott, J., Surcinelli, A., Foschi, M., Khoury, S. J., Butzkueven, H., van der Walt, A., Rous, Z., Habek, M., Meca-Lallana, J. E., Lopez, G. V., Alroughani, R., Blanco, Y., Laureys, G., Skibina, O., …, & Kerrigan, S. (2026). Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis. Brain. https://doi.org/10.1093/brain/awag252

Vancouver

Daruwalla C, Kremler C, Patti F, Ozakbas S, Boz C, Lechner-Scott J, et al. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis. Brain. 2026. doi:10.1093/brain/awag252

BibTeX
@article{Daruwalla2026,
  author = {Daruwalla, Cyrus and Kremler, Courtney and Patti, Francesco and Ozakbas, Serkan and Boz, Cavit and Lechner-Scott, Jeannette and Surcinelli, Andrea and Foschi, Matteo and Khoury, Samia J and Butzkueven, Helmut and van der Walt, Anneke and Rous, Zuzana and Habek, Mario and Meca-Lallana, Jose E and Lopez, Gabriel Valero and Alroughani, Raed and Blanco, Yolanda and Laureys, Guy and Skibina, Olga and Buzzard, Katherine and Gray, Orla and McCombe, Pamela and Maimone, Davide and Duquette, Pierre and Girard, Marc and Prat, Alexandre and Sanchez-Menoyo, Jose Luis and van Pesch, Vincent and Soysal, Aysun and Amato, Maria Pia and Grand'Maison, Francois and Wilton, Judith and Van Wijmeersch, Bart and Gerlach, Oliver and Lugaresi, Alessandra and Tomassini, Valentina and De Luca, Giovanna and Taylor, Bruce and Foong, Yi Chao and John, Nevin and Cárdenas-Robledo, Simón and Hodgkinson, Suzanne and Macdonell, Richard and Willekens, Barbara and Garber, Justin and D'Amico, Emanuele and Terzi, Murat and Houskova, Jana and Lapointe, Emmanuelle and Al-Asmi, Abdullah and Barnett, Michael and Stetkarova, Ivana and Gouider, Riadh and Mrabet, Saloua and Csepany, Tunde and McGuigan, Chris and Gross-Paju, Katrin and Kuhle, Jens and Castillo-Triviño, Tamara and Kerrigan, Simon},
  title = {Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag252}
}
Kostenlos starten →